NCT02306096 Sweden Cancerome Analysis Network - Breast : Genomic Profiling of Breast Cancer
| NCT ID | NCT02306096 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Lund University |
| Condition | Breast Neoplasms |
| Study Type | OBSERVATIONAL |
| Enrollment | 20,000 participants |
| Start Date | 2010-08 |
| Primary Completion | 2031-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 20,000 participants in total. It began in 2010-08 with a primary completion date of 2031-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study evaluates the genomic profiles of breast cancer in a prospective and population-based manner. In the first phase, breast tumors are analyzed by whole transcriptome RNA-sequencing. Gene expression profiles, mutational profiles, and transcript isoform-level data will be analyzed in the context of patient information, clinicopathological variables, and outcome, with the purpose to develop new molecular diagnostic assays for breast cancer. Additional genome-scale RNA, DNA, and protein analyses will be performed in the future.
Eligibility Criteria
Inclusion Criteria: * suspicion or confirmed diagnosis of primary breast cancer * signed informed consent Exclusion Criteria: * lack of signed informed consent
Contact & Investigator
Åke Borg, PhD
STUDY DIRECTOR
Lund University
Frequently Asked Questions
Who can join the NCT02306096 clinical trial?
This trial is open to participants of all sexes, studying Breast Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02306096 currently recruiting?
Yes, NCT02306096 is actively recruiting participants. Contact the research team at ake.borg@med.lu.se for enrollment information.
Where is the NCT02306096 trial being conducted?
This trial is being conducted at Borås, Sweden, Halmstad, Sweden, Helsingborg, Sweden, Jönköping, Sweden and 6 additional locations.
Who is sponsoring the NCT02306096 clinical trial?
NCT02306096 is sponsored by Lund University. The principal investigator is Åke Borg, PhD at Lund University. The trial plans to enroll 20,000 participants.